The novel device, known as ‘MOSkin’, detects how much radiation patients are exposed to during radiotherapy, in real time.
With nearly two-thirds of cancer patients receiving radiotherapy during their illness, inventor of the technology, Professor Anatoly Rozenfeld, said it is imperative to ensure its safety and success.
“While contemporary radiation therapy is very accurate, quality assurance during the treatment delivery is paramount because overdoses of radiation can induce chronic or acute side effects, such as skin erythema,” Professor Rozenfeld said.
“MOSkin monitors the amount of radiation the skin receives and hence this side effects can be more closely controlled.”
Professor Rozenfeld, who is the Director of the Centre for Medical Radiation Physics at UOW, said radiation overdoses could also increase the probability of secondary cancer.
“Out of field doses in children are of even greater concern. Reducing the probability of developing secondary malignancy over the lifetime of the infant is paramount,” he said. This device monitors in real time and hence can help improve techniques that minimise these out of field doses.
Due to the novel design allowing non invasive skin dose measurements the ‘MOSkin’ recently won a highly competitive Commercialisation Australia Skills and Knowledge Grant to help commercialise the technology, which has already been developed into prototypes for a range of radiotherapy treatments, and has been trialled by over 20 international cancer centres, hospitals and research institutions around Australia and internationally.
“This technology has been developed over 10 years of research, and we have received very positive scientific and clinical testing results,” Professor Rozenfeld said.
“We are pleased that both its technological value and commercial value have been acknowledged by a Chinese patent and the commercialisation grant.”
Director of Innovation and Commercial Research at UOW, Elizabeth Eastland, said: “We see the potential for the grant to open the door for further technologies in the centre’s pipeline to develop effective commercialisation opportunities. It also goes towards further highlighting the world-class research that is being undertaken at the University to address ‘real world problems’.”